Scholar Rock

150 articles about Scholar Rock

• Scholar Rock to Present at Jefferies Global Healthcare Conference 2022

  6/2/2022

  Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 8:00 a.m. ET.

• 

  Scholar Rock Slashes Headcount by 25% as it Advances SMA Therapeutic

  5/17/2022

  As Scholar Rock prepares to move forward with its experimental assets for spinal muscular atrophy, it has terminated 25% of its staff and also announced the loss of its chief medical officer.

• Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities

  5/16/2022

  Scholar Rock, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, provided a business update and reported financial results for the first quarter ended March 31, 2022.

• Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress

  4/21/2022

  Scholar Rock today announced that it is delivering a podium presentation at the 14th European Paediatric Neurology Society (EPNS) Congress, taking place in Glasgow, UK from April 28 - May 2, 2022.

• Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting

  3/22/2022

  Scholar Rock today announced that it is presenting encore data in an e-poster at the American Academy of Neurology (AAN) 2022 Annual Meeting, taking place in Seattle, Washington (April 2-7) and virtually (April 24-26).

• Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

  3/13/2022

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that it will present a poster at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference.

• Scholar Rock Reports Full Year 2021 Financial Results and Highlights Business Progress

  3/7/2022

  Scholar Rock today reported financial results for the full year ended December 31, 2021, and highlighted recent progress and upcoming milestones for its pipeline programs.

• Scholar Rock to Present at Cowen’s 42nd Annual Health Care Conference

  2/25/2022

  Scholar Rock to Present at Cowen’s 42nd Annual Health Care Conference.

• Scholar Rock Provides Corporate Update and Highlights Priorities for 2022

  1/10/2022

  Scholar Rock today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2022.

• Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/4/2022

  Scholar Rock today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 7:30 a.m. ET.

• Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress

  11/9/2021

  Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress

• Scholar Rock to Present at Upcoming Healthcare Conferences - Nov 02, 2021

  11/2/2021

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that management will participate in the following upcoming investor conferences.

• Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology

  10/3/2021

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced an e-poster presentation of clinical results from the TOPAZ Phase 2 trial that evaluated apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy at the 25th World Congress of Neurology taking place October 3-7, 2021.

•  Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation

  9/28/2021

  Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation

•  Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

  9/23/2021

    Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

• Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference

  9/22/2021

  Scholar Rock today announced that management will present at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29 th , 2021 at 11:20 a.m. ET.

• Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

  8/16/2021

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer.

• Scholar Rock Reports Second Quarter 2021 Financial Results and Highlights Business Progress

  8/10/2021

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, reported financial results for the second quarter ended June 30, 2021, and highlighted recent progress and upcoming milestones for its pipeline programs.

• Scholar Rock to Present at the 2021 Wedbush PacGrow Healthcare Conference

  8/5/2021

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that management will present at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11th, 2021 at 9:10 a.m. ET.

• Scholar Rock Announces Leadership Change

  8/3/2021

  Nagesh Mahanthappa, Ph.D., MBA, Scholar Rock’s founding chief executive, returns as Interim Chief Executive Officer as CEO Tony Kingsley departs